Literature DB >> 1312007

Inhibition of platelet-derived growth factor-induced mitogenesis and tyrosine kinase activity in cultured bone marrow fibroblasts by tyrphostins.

M C Bryckaert1, A Eldor, M Fontenay, A Gazit, N Osherov, C Gilon, A Levitzki, G Tobelem.   

Abstract

Tyrphostins, which block protein tyrosine kinase activity, were studied for their inhibitory action on platelet-derived growth factor (PDGF)-induced proliferation of human bone marrow fibroblasts. Of the seven tryphostins examined, tyrphostin AG370 was found to be the most potent blocker against PDGF-induced mitogenesis (IC50 = 20 microM). This PTK blocker also blocks mitogenesis induced by epidermal growth factor (IC50 = 50 microM) and human serum (IC50 = 50 microM), but with lower efficacy. In digitonin-permeabilized fibroblasts as well as in intact fibroblasts, tyrphostin AG370 inhibits PDGF receptor autophosphorylation and the tyrosine phosphorylation of intracellular protein substrates (pp120, pp85, and pp75) which coprecipitate with the PDGF receptor. In comparison to AG370, AG18, a potent EGF receptor blocker, was less efficient in inhibiting PDGF-induced proliferation of fibroblasts and phosphorylation of the intracellular protein substrates. Under the conditions in which AG370 inhibits PDGF-induced mitogenesis and phosphorylation, it does not affect [125I]PDGF internalization and enhance [125I]PDGF binding. These findings suggest that AG370, which is an indole tyrphostin, may serve as a model for developing analogues with a therapeutic potential for treatment of diseases which involve abnormal cellular proliferation induced by PDGF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312007     DOI: 10.1016/0014-4827(92)90432-8

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway.

Authors:  Roy Barco; Laura B Hunt; Andrea L Frump; Christina B Garcia; Andrew Benesh; Robert L Caldwell; Josiane E Eid
Journal:  Mol Biol Cell       Date:  2007-08-08       Impact factor: 4.138

2.  Interdependence of platelet-derived growth factor and estrogen-signaling pathways in inducing neonatal rat testicular gonocytes proliferation.

Authors:  Raphael Thuillier; Monty Mazer; Gurpreet Manku; Annie Boisvert; Yan Wang; Martine Culty
Journal:  Biol Reprod       Date:  2010-01-20       Impact factor: 4.285

Review 3.  Targeting signal transduction for disease therapy.

Authors:  A Levitzki
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

4.  Role of retinoic acid and platelet-derived growth factor receptor cross talk in the regulation of neonatal gonocyte and embryonal carcinoma cell differentiation.

Authors:  Gurpreet Manku; Yan Wang; Vanessa Merkbaoui; Annie Boisvert; Xiaoying Ye; Josip Blonder; Martine Culty
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

5.  Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Authors:  E Buchdunger; J Zimmermann; H Mett; T Meyer; M Müller; U Regenass; N B Lydon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  The tyrosine kinase FRK/RAK participates in cytokine-induced islet cell cytotoxicity.

Authors:  Michael Welsh; Charlotte Welsh; Maria Ekman; Johan Dixelius; Robert Hägerkvist; Cecilia Annerén; Björn Akerblom; Siavosh Mahboobi; Subhashini Chandrasekharan; Edison T Liu
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

7.  Intrinsic regulation of hemangioma involution by platelet-derived growth factor.

Authors:  E E Roach; R Chakrabarti; N I Park; E C Keats; J Yip; N G Chan; Z A Khan
Journal:  Cell Death Dis       Date:  2012-06-21       Impact factor: 8.469

8.  Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.

Authors:  J Gillespie; J F Dye; M Schachter; P J Guillou
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.